# Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

> **NCT02981303** · PHASE2 · COMPLETED · sponsor: **HiberCell, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Advanced Melanoma
- Triple-Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Imprime PGG
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02981303
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-22
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981303, "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02981303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*